Present Preliminary Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Amolyt Pharma
Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021
Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021
Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting
LYON, France and NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the Endocrine Society’s Annual Meeting, ENDO 2021, being held virtually from March 20-23, 2021. ....

United States , Ashley Robinson , Amolyt Pharma , Cherilyn Cecchini , Lifesci Advisors , Lifesci Communications , Endocrine Society Annual Meeting , A Single Administration , Present Preliminary Phase , Additional Preclinical Data , Endocrine Society , Annual Meeting , Single Administration , Sustained Calcemic Response , Preliminary Data From , Placebo Controlled Phase , Rare Bone , Claims Data Analysis Using Diagnosis Based , Claims Data Analysis Using Surgery Based , Peptide Analog , Induces Weight Loss , Improves Glucose Metabolism , Novel Mechanisms , Sci Advisors , Investegate Announcements , Investegate Company Announcements ,